|Slideshows|September 9, 2019

Bipolar Disorder: Psychosis, Mania, and Additional Research

Call for better first-episode mania care, brain activation patterns predict risk, what’s important about atypical antipsychotics- find concise summaries of these and other key developments here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

The 5 Faces of Bipolar Depression: A Case-Based Reflection

ByHameed Younis, MD

August 26th 2026

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

ByDavid N. Osser, MD

August 18th 2026

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

Categories vs Dimensions: Wave or Particle?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

July 29th 2026

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Bipolar Disorder: Psychosis, Mania, and Additional Research

Related Content

The 5 Faces of Bipolar Depression: A Case-Based Reflection

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Categories vs Dimensions: Wave or Particle?

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness